Retatrutide Phase 2 and Phase 3 Trial Registry
Some of the more common side effects in clinical trials compared to placebo include: Gastrointestinal side effects such as nausea, vomiting, constipation, or diarrhea Abdominal pain Headache, dizziness Fatigue Dyspepsia, abdominal distension, eructation Hypoglycemia (low blood sugar) in patients with type 2 diabetes Flatulence, gastroenteritis, and gastroesophageal reflux disease (heartburn) Hypoglycemia (low blood sugar levels), a more serious side effect of GLP-1 drugs, may also occur
The interaction between growth hormone pathway activation and triple-receptor incretin agonism has zero clinical data supporting its safety or efficacy
While it helps to leverage existing real-world data for cost-effective and time-efficient insights, this method can be challenged by potential biases, missing data, and lack of control over variables or study design
You might remember the old rhyme: Beans, beans, theyre good for your heart. That rhyme hints at fermentation: fiber in beans leads to SCFAs, which help trigger GLP-1
There is currently no published evidence confirming the safety of taking tesamorelin and retatrutide together
